Skip to main content
. 2017 Sep 8;8(60):101383–101393. doi: 10.18632/oncotarget.20711

Figure 2.

Figure 2

Figure 2

Kaplan-Meier curves of progression-free survival (A) and overall survival (B) from the start of second-line chemotherapy with (dashed line) or without (solid line) trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction adenocarcinoma.